Other HIV — Total revenues
Gilead Sciences Other HIV — Total revenues decreased by 61.6% to $73.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 19.8%, from $91.00M to $73.00M. Over 3 years (FY 2022 to FY 2025), Other HIV — Total revenues shows relatively stable performance with a -1.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests successful lifecycle management or sustained demand for secondary therapies, while a decrease may indicate product obsolescence or market share erosion by newer, more effective treatments.
Detailed definition
This metric represents the total revenue generated from the company's secondary or legacy HIV product portfolio, excludi...
Peer comparison
Peers in the pharmaceutical industry typically report similar secondary segment revenues to track the tail-end performance of older drug portfolios versus high-growth flagship products.
gild_segment_other_hiv_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $132.50M | $132.50M | $132.50M | $132.50M | $100.25M | $100.25M | $100.25M | $100.25M | $117.00M | $105.00M | $100.00M | $112.00M | $91.00M | $107.00M | $112.00M | $190.00M | $73.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -24.3% | +0.0% | +0.0% | +0.0% | +16.7% | -10.3% | -4.8% | +12.0% | -18.8% | +17.6% | +4.7% | +69.6% | -61.6% |
| YoY Change | — | — | — | — | -24.3% | -24.3% | -24.3% | -24.3% | +16.7% | +4.7% | -0.2% | +11.7% | -22.2% | +1.9% | +12.0% | +69.6% | -19.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's other hiv — total revenues?
- Gilead Sciences (GILD) reported other hiv — total revenues of $73.00M in Q1 2026.
- How has Gilead Sciences's other hiv — total revenues changed year-over-year?
- Gilead Sciences's other hiv — total revenues decreased by 19.8% year-over-year, from $91.00M to $73.00M.
- What is the long-term trend for Gilead Sciences's other hiv — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's other hiv — total revenues has grown at a -1.9% compound annual growth rate (CAGR), from $530.00M to $500.00M.
- What does other hiv — total revenues mean?
- The total sales revenue generated from secondary or niche HIV treatment products.